Introduction: Biosimilar development is analytically demanding. Regulatory agencies — Health Canada, the FDA, and the EMA alike — require manufacturers […]
Introduction: Selecting the correct sterilization methods for PLGA drug products is one of the most consequential decisions in pharmaceutical formulation
Introduction: Nitrosamine testing for metformin is no longer optional — it is a regulatory and patient safety requirement that every
Introduction: Lifecycle management strategies for dexamethasone injectables are essential for pharmaceutical manufacturers aiming to sustain product relevance, regulatory compliance, and
Lifecycle Management Strategies for Dexamethasone Injectables Read More »
Introduction: Method validation for extractables and leachables testing is a regulatory non-negotiable — without a fully documented, ICH Q2(R2)-compliant validation
Method Validation for Extractables and Leachables Testing: What ICH Q2(R2) Requires Read More »
Introduction: A receptor-targeted peptide oligonucleotide conjugate (POC) is an engineered biotherapeutic that links an antisense oligonucleotide (ASO) payload to a
Introduction: Why Immunogenicity Assessment in Biosimilar Development Is Non-Negotiable Immunogenicity assessment in biosimilar development refers to the structured process of
Introduction: The landscape of incretin-based therapies has expanded far beyond the first-generation GLP-1 receptor agonists. Regulatory submissions for GLP-2 and
Summary: Introduction: Why PLGA Analytical Data for Injectable Use Demands a Higher Standard When procuring poly(lactic-co-glycolic acid) for parenteral formulations,
What Analytical Data Should You Request When Buying PLGA for Injectable Use? Read More »
Introduction: The convergence of peptide chemistry and oligonucleotide biology has produced one of the most promising — and analytically demanding
